Skip to main content
Top
Published in: Current Fungal Infection Reports 4/2017

01-12-2017 | Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Onychomycosis and Immunodepression

Authors: Patricia Chang, Zonia Maria Quijada Ucelo, Helena Maria del Pilar Garzaro Chávez

Published in: Current Fungal Infection Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

This review summarizes the most relevant information on onychomycosis in patients with immunosuppressive disorders and also compares the distinctive characteristics and approach with the general population.

Recent Findings

Onychomycosis in immunocompromised patients has a similar clinical presentation to the one in the general population, yet there are still differences. For instance, the white variety also known as mycotic leukonychia is characteristic among the group, being more common among patients with HIV/AIDS. Proximal subungual onychomycosis (PSO) and white superficial onychomycosis (WSO) have been proposed as markers of disease progression among HIV patients. Among the diabetic, onychomycosis in general has been found closely linked with complications.

Summary

The prevalence of onychomycosis in immunocompromised patients is up to three times higher when compared the one described in the general population, representing an important public health problem, closely related to the patient’s quality of life. Therefore, it is important to identify the characteristic clinical presentation among this group of patients, diagnose accordingly, and initiate appropriate therapy to avoid complications and improve outcome.
Literature
1.
go back to reference Garmendia J, Viedma P, et al. Onychomycosis: diagnosis and treatment. Inf Ter Sist Nac Salud. 2008;32:83–92. Garmendia J, Viedma P, et al. Onychomycosis: diagnosis and treatment. Inf Ter Sist Nac Salud. 2008;32:83–92.
2.
go back to reference Bonifaz A. Micología superficial y pseudomicología: onicomicosis. In: Micología Médica Básica. Mexico: Mc Graw Hill; 2012;106–109. Bonifaz A. Micología superficial y pseudomicología: onicomicosis. In: Micología Médica Básica. Mexico: Mc Graw Hill; 2012;106–109.
3.
go back to reference Tully A, Trayes K, et al. Evaluation of nail abnormalities. Am Fam Physician. 2012;85:779–87.PubMed Tully A, Trayes K, et al. Evaluation of nail abnormalities. Am Fam Physician. 2012;85:779–87.PubMed
7.
go back to reference Chang P, Arenas R, Cabrera L. Mycotic leukonychia in non-dermatologic patients. Report of 10 cases. Dermatología CMQ. 2010;8:8–12. Chang P, Arenas R, Cabrera L. Mycotic leukonychia in non-dermatologic patients. Report of 10 cases. Dermatología CMQ. 2010;8:8–12.
9.
go back to reference Llahyah Y, Ferrini D, Mercau S, et al. Onychomycosis in HIV-positive patients. Dermatol Argent. 2013;1:34–8. Llahyah Y, Ferrini D, Mercau S, et al. Onychomycosis in HIV-positive patients. Dermatol Argent. 2013;1:34–8.
10.
go back to reference Cribier B, Leiva M, Grosshans L, et al. Nail changes in patients infected with human immunodeficiency virus. Arch Dermatol. 1998;134:1216–20.PubMed Cribier B, Leiva M, Grosshans L, et al. Nail changes in patients infected with human immunodeficiency virus. Arch Dermatol. 1998;134:1216–20.PubMed
11.
go back to reference Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol. 2000;39:746–53.CrossRefPubMed Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol. 2000;39:746–53.CrossRefPubMed
16.
go back to reference •• Elbendary A, El Tawdy A, Zaki N, et al. Subclinical onychomycosis in patients with type II diabetes. Dermatol Rep. 2015;7:6099. https://doi.org/10.4081/dr.2015.6099. A study that supports that not all diabetic patients with onychomycosis have clinical manifestations, early detection using nail clipping and microscopic examination with PAS in addition with treatment can prevent serious complications. CrossRef •• Elbendary A, El Tawdy A, Zaki N, et al. Subclinical onychomycosis in patients with type II diabetes. Dermatol Rep. 2015;7:6099. https://​doi.​org/​10.​4081/​dr.​2015.​6099. A study that supports that not all diabetic patients with onychomycosis have clinical manifestations, early detection using nail clipping and microscopic examination with PAS in addition with treatment can prevent serious complications. CrossRef
20.
go back to reference • Oz Y, Qoraan I, Balta I, et al. Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey. Int J Dermatol. 2017;1:68–74. https://doi.org/10.1111/ijd.13402. A study showing that isolation and identification of the fungus is important to the effective management of tinea pedis and onychomycosis in diabetes patients because non-dermatophyte fungi can cause these infections. CrossRef • Oz Y, Qoraan I, Balta I, et al. Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey. Int J Dermatol. 2017;1:68–74. https://​doi.​org/​10.​1111/​ijd.​13402. A study showing that isolation and identification of the fungus is important to the effective management of tinea pedis and onychomycosis in diabetes patients because non-dermatophyte fungi can cause these infections. CrossRef
21.
go back to reference Leelavathi M, Azimah M, et al. Prevalence of toenail onychomycosis among diabetics at a primary care facility in Malaysia. Southeast Asian J Trop Med Public Health. 2013;44:479–83.PubMed Leelavathi M, Azimah M, et al. Prevalence of toenail onychomycosis among diabetics at a primary care facility in Malaysia. Southeast Asian J Trop Med Public Health. 2013;44:479–83.PubMed
22.
go back to reference Al-Mutairi N, Eassa B, Al-Rqobah D. Clinical and mycologic characteristics of onychomycosis in diabetic patients. Acta Dermatovenerol Croat. 2010;18:84–91.PubMed Al-Mutairi N, Eassa B, Al-Rqobah D. Clinical and mycologic characteristics of onychomycosis in diabetic patients. Acta Dermatovenerol Croat. 2010;18:84–91.PubMed
26.
go back to reference Lamb FM, Ottonelli S, et al. Frequency of onychomycoses in chronic renal failure patients undergoing hemodialysis in Porto Alegre, Brazil. Acta Dermatovenerol Croat. 2013;1:19–23. Lamb FM, Ottonelli S, et al. Frequency of onychomycoses in chronic renal failure patients undergoing hemodialysis in Porto Alegre, Brazil. Acta Dermatovenerol Croat. 2013;1:19–23.
28.
go back to reference • Araiza-Santibánez J, Tirado-Sánchez A, González-Rodríguez A, et al. Onychomycosis in the elderly. A 2-year retrospective study of 138 cases. Rev Med Hosp Gen Mex. 2016;79:5–10. https://doi.org/10.1016/j.hgmx.2015.10.004. A retrospective study showing the presence of common comorbidities such as hypertension or diabetes mellitus in elderly population can complicate the therapeutic management, mainly because the yeast infection is as common as dermatophytes. • Araiza-Santibánez J, Tirado-Sánchez A, González-Rodríguez A, et al. Onychomycosis in the elderly. A 2-year retrospective study of 138 cases. Rev Med Hosp Gen Mex. 2016;79:5–10. https://​doi.​org/​10.​1016/​j.​hgmx.​2015.​10.​004. A retrospective study showing the presence of common comorbidities such as hypertension or diabetes mellitus in elderly population can complicate the therapeutic management, mainly because the yeast infection is as common as dermatophytes.
29.
go back to reference Boonchai W, Kulthanan K, Maungprasat C, Suthipinittham P. Clinical characteristics and mycology of onychomycosis in autoimmune patients. J Med Assoc Thai. 2003;86:995–1000.PubMed Boonchai W, Kulthanan K, Maungprasat C, Suthipinittham P. Clinical characteristics and mycology of onychomycosis in autoimmune patients. J Med Assoc Thai. 2003;86:995–1000.PubMed
Metadata
Title
Onychomycosis and Immunodepression
Authors
Patricia Chang
Zonia Maria Quijada Ucelo
Helena Maria del Pilar Garzaro Chávez
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 4/2017
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-017-0292-7

Other articles of this Issue 4/2017

Current Fungal Infection Reports 4/2017 Go to the issue

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Onychomycoses in a Military Population in Brazil

Fungal Genomics and Pathogenesis (Shmuel Shoham, Section Editor)

What Is New? Recent Knowledge on Fungal Extracellular Vesicles

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.